These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9773732)

  • 1. Effect of bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM.
    Elliott JF; Marlin KL; Couch RM
    Diabetes Care; 1998 Oct; 21(10):1691-3. PubMed ID: 9773732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study.
    Allen HF; Klingensmith GJ; Jensen P; Simoes E; Hayward A; Chase HP
    Diabetes Care; 1999 Oct; 22(10):1703-7. PubMed ID: 10526739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM.
    Schnell O; Eisfelder B; Standl E; Ziegler AG
    Diabetes; 1997 Oct; 46(10):1607-11. PubMed ID: 9313757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
    Pozzilli P; Visalli N; Signore A; Baroni MG; Buzzetti R; Cavallo MG; Boccuni ML; Fava D; Gragnoli C; Andreani D
    Diabetologia; 1995 Jul; 38(7):848-52. PubMed ID: 7556988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Effects of BCG Vaccination on Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chang YC; Lin CJ; Hsiao YH; Chang YH; Liu SJ; Hsu HY
    J Diabetes Res; 2020; 2020():8954125. PubMed ID: 32309449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proinsulin immunoreactivity in recent-onset IDDM: the significance of insulin antibodies and insulin autoantibodies.
    Snorgaard O; Kjems LL; Røder ME; Hartling SG; Dinesen B; Binder C
    Diabetes Care; 1996 Feb; 19(2):146-50. PubMed ID: 8718435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr.
    Snorgaard O; Lassen LH; Binder C
    Diabetes Care; 1992 Aug; 15(8):1009-13. PubMed ID: 1505301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study.
    Pozzilli P; Visalli N; Boccuni ML; Baroni MG; Buzzetti R; Fioriti E; Signore A; Cavallo MG; Andreani D; Lucentini L
    Diabetes Care; 1994 Aug; 17(8):897-900. PubMed ID: 7956639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCG vaccine in insulin-dependent diabetes mellitus. IMDIAB Group.
    Pozzilli P
    Lancet; 1997 May; 349(9064):1520-1. PubMed ID: 9167468
    [No Abstract]   [Full Text] [Related]  

  • 10. Soluble CD8 antigen, stimulated C-peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassifiable diabetes.
    Di Bonito P; De Bellis A; Capaldo B; Turco S; Corigliano G; Pace E; Bizzarro A
    Acta Diabetol; 1996 Sep; 33(3):220-4. PubMed ID: 8904929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
    Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
    Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
    Lazar L; Ofan R; Weintrob N; Avron A; Tamir M; Elias D; Phillip M; Josefsberg Z
    Diabetes Metab Res Rev; 2007 May; 23(4):286-91. PubMed ID: 17124721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group.
    J Clin Endocrinol Metab; 1987 Jul; 65(1):30-6. PubMed ID: 2884229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
    Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
    N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus.
    Chase HP; Butler-Simon N; Garg S; McDuffie M; Hoops SL; O'Brien D
    Diabetologia; 1990 Jul; 33(7):444-6. PubMed ID: 2144835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.
    Taha DR; Castells S; Umpaichitra V; Bastian W; Banerji MA
    J Pediatr Endocrinol Metab; 2002 Jan; 15(1):59-67. PubMed ID: 11822582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of insulin secretion and insulin resistance in the clinical course of newly diagnosed diabetes mellitus in children].
    Szadkowska A; Pietrzak I; Markuszewski L; Bodalski J
    Med Wieku Rozwoj; 2005; 9(2):223-34. PubMed ID: 16085963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes.
    Picardi A; Visalli N; Lauria A; Suraci C; Buzzetti R; Merola MK; Manfrini S; Guglielmi C; Gentilucci UV; Pitocco D; Crinò A; Bizzarri C; Cappa M; Pozzilli P
    Horm Metab Res; 2006 Oct; 38(10):668-72. PubMed ID: 17075776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
    Couri CE; Oliveira MC; Stracieri AB; Moraes DA; Pieroni F; Barros GM; Madeira MI; Malmegrim KC; Foss-Freitas MC; Simões BP; Martinez EZ; Foss MC; Burt RK; Voltarelli JC
    JAMA; 2009 Apr; 301(15):1573-9. PubMed ID: 19366777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.